ATE213157T1 - Verwendung von alpha-aminomethyl-3,4- dichlorbenzylthioaceamiden zur herstellung eines dopaminwiederergreifungshemmenden medikaments sowie verbindungen zur verwendung derselben - Google Patents

Verwendung von alpha-aminomethyl-3,4- dichlorbenzylthioaceamiden zur herstellung eines dopaminwiederergreifungshemmenden medikaments sowie verbindungen zur verwendung derselben

Info

Publication number
ATE213157T1
ATE213157T1 AT96401061T AT96401061T ATE213157T1 AT E213157 T1 ATE213157 T1 AT E213157T1 AT 96401061 T AT96401061 T AT 96401061T AT 96401061 T AT96401061 T AT 96401061T AT E213157 T1 ATE213157 T1 AT E213157T1
Authority
AT
Austria
Prior art keywords
alpha
dopamine
dichlorobenzylthioaceamide
reapposition
aminomethyl
Prior art date
Application number
AT96401061T
Other languages
English (en)
Inventor
Philippe Laurent
Original Assignee
Lafon Labor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lafon Labor filed Critical Lafon Labor
Application granted granted Critical
Publication of ATE213157T1 publication Critical patent/ATE213157T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/56Ring systems containing bridged rings
    • C07C2603/58Ring systems containing bridged rings containing three rings
    • C07C2603/70Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96401061T 1995-05-19 1996-05-14 Verwendung von alpha-aminomethyl-3,4- dichlorbenzylthioaceamiden zur herstellung eines dopaminwiederergreifungshemmenden medikaments sowie verbindungen zur verwendung derselben ATE213157T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9506000A FR2734264B1 (fr) 1995-05-19 1995-05-19 Utilisation de derives d'alpha-aminomethyl-3,4-dichlorobenzyl-thioacetamide pour la fabrication d'un medicament inhibant la recapture de la dopamine et nouveaux composes pour cette utilisation

Publications (1)

Publication Number Publication Date
ATE213157T1 true ATE213157T1 (de) 2002-02-15

Family

ID=9479198

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96401061T ATE213157T1 (de) 1995-05-19 1996-05-14 Verwendung von alpha-aminomethyl-3,4- dichlorbenzylthioaceamiden zur herstellung eines dopaminwiederergreifungshemmenden medikaments sowie verbindungen zur verwendung derselben

Country Status (14)

Country Link
US (2) US5795915A (de)
EP (1) EP0743063B1 (de)
JP (1) JP3926867B2 (de)
KR (1) KR960041159A (de)
AT (1) ATE213157T1 (de)
AU (1) AU713215B2 (de)
CA (1) CA2176654A1 (de)
DE (1) DE69619156T2 (de)
DK (1) DK0743063T3 (de)
ES (1) ES2172644T3 (de)
FR (1) FR2734264B1 (de)
NZ (1) NZ286602A (de)
PT (1) PT743063E (de)
ZA (1) ZA963846B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11162829A (ja) * 1997-11-21 1999-06-18 Nec Corp 半導体装置の製造方法
EP1148538A4 (de) * 1998-12-25 2009-10-21 Hitachi Chemical Co Ltd Cmp-schleifmittel, flüssigzusatz für dasselbe und substratpoliermethode
ATE424194T1 (de) 2001-04-09 2009-03-15 Neurosearch As Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2561646B1 (fr) * 1984-03-23 1987-10-09 Lafon Labor Derives d'acide (a-(alkylaminomethyl)-benzyl)-thioacetique, procede de preparation et utilisation en therapeutique
FR2648814B1 (fr) * 1989-06-26 1991-10-18 Lafon Labor L'alpha (tert-butyl-aminomethyl-3,4-dichlorobenzyl)thioacetamide, son procede de preparation et son application en therapeutique
AU3707601A (en) 2000-02-08 2001-08-20 Vagas amusment incorperated Method of and apparatus for operating a video lottery terminal

Also Published As

Publication number Publication date
US6268397B1 (en) 2001-07-31
PT743063E (pt) 2002-07-31
DK0743063T3 (da) 2002-06-03
DE69619156T2 (de) 2002-08-14
CA2176654A1 (en) 1996-11-20
DE69619156D1 (de) 2002-03-21
US5795915A (en) 1998-08-18
ZA963846B (en) 1997-11-17
ES2172644T3 (es) 2002-10-01
EP0743063A1 (de) 1996-11-20
FR2734264B1 (fr) 1997-08-01
JP3926867B2 (ja) 2007-06-06
FR2734264A1 (fr) 1996-11-22
NZ286602A (en) 1997-04-24
JPH093039A (ja) 1997-01-07
AU713215B2 (en) 1999-11-25
KR960041159A (ko) 1996-12-19
AU5233896A (en) 1996-11-28
EP0743063B1 (de) 2002-02-13

Similar Documents

Publication Publication Date Title
BRPI0509368A (pt) antagonistas cgrp selecionados, processo para a sua fabricação bem como seu uso como medicamento
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
IN2015DN01132A (de)
SE0202429D0 (sv) Novel Compounds
BR0016611A (pt) Moduladores de neurotransmissão de dopamina
NO20042161L (no) Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
MX9203444A (es) Medicamentos.
EA200500080A1 (ru) Дозированная форма прамипексола, принимаемая один раз в день
AR034396A1 (es) Compuestos 4-(1r-4-piperidilen)-4h-benzo[4,5]ciclohepta[1,2]-tiofeno-1-a y sus isomeros opticamente activos, un metodo para su sintesis y el uso de dichos compuestos para la manufactura de un medicamento
NO20045222L (no) Benzosyrederivater som modulatorer av PPAR alfa og gamma
NO20045486L (no) Nye forbindelser og deres anvendelse
NO20050217L (no) Nye quinuklidin-karbamat-derivater samt medisinske sammensetninger inneholdende slike
UA35604C2 (uk) Фармацевтична композиція з антидепресивною активністю
AR043259A1 (es) Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
DE602004024417D1 (de) Neues verfahren zur herstellung von pleuromutilinderivaten
SE9904507D0 (sv) New compounds
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
MXPA02012730A (es) Uso de acido pamoico o uno de sus derivados o uno de sus analogos para la preparacion de un medicamento para el tratamiento de enfermedades caracterizadas por depositos de agregados de amiloide.
ATE213157T1 (de) Verwendung von alpha-aminomethyl-3,4- dichlorbenzylthioaceamiden zur herstellung eines dopaminwiederergreifungshemmenden medikaments sowie verbindungen zur verwendung derselben
NO20050903L (no) Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser
ATE214051T1 (de) Substituierte tetrahydropyridinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DK0672043T3 (da) Hidtil ukendte 4-(3-benzofuranyl)-piperidinyl- og 4-(3-benzothienyl)-piperidinyl-derivater og farmaceutiske præparater indeholdende dem
SE0104333D0 (sv) Therapeutic agents

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee